Literature DB >> 3279137

Analysis of C3 deposition and degradation on bacterial surfaces after opsonization.

D L Gordon1, J Rice, J J Finlay-Jones, P J McDonald, M K Hostetter.   

Abstract

C3b and iC3b, opsonic fragments of C3, interact with specific receptors on phagocytic cells. After bacterial opsonization, C3 fragments were analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis, western blotting, and immunodetection. For bacteria opsonized in 50% pooled human serum (PHS), C3 deposition and cleavage to iC3b occurred rapidly. C3b, iC3b, and C3d made up 17%, 64%, and 19%, respectively, of the C3 on Staphylococcus aureus and 53%, 44%, and 2% respectively, on Escherichia coli. Residual C3b was refractory to factor I cleavage, an occurrence enabling alternative pathway activation to continue. C3 deposited was quantitated by enzyme-linked immunosorbent assay; with 50% PHS, greater than 50% and 90% of total C3 deposition occurred within 5 and 10 min, respectively. With a lower percentage of PHS, maximal deposition required up to 60 min and was not achieved in less than 10% PHS. Ester-bound fragments represented 34% and 82% of covalently bound C3 on S. aureus and E. coli, respectively.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3279137     DOI: 10.1093/infdis/157.4.697

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  39 in total

1.  Pneumococcal surface protein A inhibits complement activation by Streptococcus pneumoniae.

Authors:  A H Tu; R L Fulgham; M A McCrory; D E Briles; A J Szalai
Journal:  Infect Immun       Date:  1999-09       Impact factor: 3.441

2.  Genetic alteration of capsule type but not PspA type affects accessibility of surface-bound complement and surface antigens of Streptococcus pneumoniae.

Authors:  Melanie Abeyta; Gail G Hardy; Janet Yother
Journal:  Infect Immun       Date:  2003-01       Impact factor: 3.441

3.  Deposition and degradation of C3 on type III group B streptococci.

Authors:  J R Campbell; C J Baker; M S Edwards
Journal:  Infect Immun       Date:  1991-06       Impact factor: 3.441

Review 4.  Immunological risk of injectable drug delivery systems.

Authors:  Wim Jiskoot; Rianne M F van Schie; Myrra G Carstens; Huub Schellekens
Journal:  Pharm Res       Date:  2009-02-27       Impact factor: 4.200

5.  Sialylation of Neisseria meningitidis lipooligosaccharide inhibits serum bactericidal activity by masking lacto-N-neotetraose.

Authors:  M M Estabrook; J M Griffiss; G A Jarvis
Journal:  Infect Immun       Date:  1997-11       Impact factor: 3.441

6.  Mesophilic Aeromonas sp. serogroup O:11 resistance to complement-mediated killing.

Authors:  S Merino; X Rubires; A Aguilar; S Albertí; S Hernandez-Allés; V J Benedí; J M Tomas
Journal:  Infect Immun       Date:  1996-12       Impact factor: 3.441

7.  Complement factor C3 deposition and serum resistance in isogenic capsule and lipooligosaccharide sialic acid mutants of serogroup B Neisseria meningitidis.

Authors:  U Vogel; A Weinberger; R Frank; A Müller; J Köhl; J P Atkinson; M Frosch
Journal:  Infect Immun       Date:  1997-10       Impact factor: 3.441

8.  Complement-mediated phagocytosis of herpes simplex virus by granulocytes. Binding or ingestion.

Authors:  J A Van Strijp; K P Van Kessel; M E van der Tol; J Verhoef
Journal:  J Clin Invest       Date:  1989-07       Impact factor: 14.808

9.  Specificity of bovine serum antibody to capsular carbohydrate antigens from Pasteurella haemolytica.

Authors:  D S McVey; R W Loan; C W Purdy; W J Shuman
Journal:  J Clin Microbiol       Date:  1990-06       Impact factor: 5.948

10.  Cleavage of complement C3b to iC3b on the surface of Staphylococcus aureus is mediated by serum complement factor I.

Authors:  K M Cunnion; P S Hair; E S Buescher
Journal:  Infect Immun       Date:  2004-05       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.